Wall Street Zen Upgrades Collegium Pharmaceutical (NASDAQ:COLL) to Buy

Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Saturday, Wall Street Zen reports.

Other research analysts have also issued reports about the stock. Leerink Partners began coverage on shares of Collegium Pharmaceutical in a research note on Wednesday, September 9th. They set an “outperform” rating and a $45.00 price objective on the stock. Truist Financial assumed coverage on shares of Collegium Pharmaceutical in a report on Wednesday, September 9th. They issued a “buy” rating and a $49.00 price target on the stock. Jefferies Financial Group reaffirmed a “buy” rating and set a $35.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday. Weiss Ratings lowered Collegium Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, September 4th. Finally, Barclays cut their price objective on Collegium Pharmaceutical from $56.00 to $48.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 19th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $44.88.

Collegium Pharmaceutical Trading Down 3.8%

Collegium Pharmaceutical stock opened at $24.21 on Friday. The company has a current ratio of 1.03, a quick ratio of 0.84 and a debt-to-equity ratio of 3.32. Collegium Pharmaceutical has a 12 month low of $21.43 and a 12 month high of $50.79. The business’s fifty day simple moving average is $22.99 and its two-hundred day simple moving average is $32.79. The company has a market capitalization of $788.28 million, a price-to-earnings ratio of 3.39, a price-to-earnings-growth ratio of 0.74 and a beta of 0.75.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, November 5th. The specialty pharmaceutical company reported $1.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.86 by $0.10. The firm had revenue of $216.34 million for the quarter, compared to analyst estimates of $216.03 million. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%. The business’s revenue was up 67.4% on a year-over-year basis. During the same quarter last year, the firm posted $2.25 EPS. As a group, equities analysts predict that Collegium Pharmaceutical will post 6.42 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Ritholtz Wealth Management lifted its stake in shares of Collegium Pharmaceutical by 150.7% in the 3rd quarter. Ritholtz Wealth Management now owns 20,305 shares of the specialty pharmaceutical company’s stock valued at $443,000 after acquiring an additional 12,205 shares during the last quarter. Illinois Municipal Retirement Fund increased its position in Collegium Pharmaceutical by 10.0% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 17,696 shares of the specialty pharmaceutical company’s stock valued at $386,000 after purchasing an additional 1,607 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Collegium Pharmaceutical during the third quarter worth $36,000. Profund Advisors LLC raised its position in Collegium Pharmaceutical by 621.1% in the third quarter. Profund Advisors LLC now owns 65,710 shares of the specialty pharmaceutical company’s stock valued at $1,434,000 after purchasing an additional 56,597 shares during the period. Finally, Vise Technologies Inc. increased its position in Collegium Pharmaceutical by 154.3% during the third quarter. Vise Technologies Inc. now owns 14,844 shares of the specialty pharmaceutical company’s stock worth $324,000 after buying an additional 9,006 shares during the period.

Trending Headlines about Collegium Pharmaceutical

Here are the key news stories impacting Collegium Pharmaceutical this week:

• Positive Sentiment: Q3 adjusted earnings of $1.96 per share topped consensus estimates, and revenue of $216.3 million narrowly beat expectations. The company reported record quarterly revenue, including JORNAY PM revenue up 24% year over year. Collegium Q3 2026 results
• Positive Sentiment: FY 2026 revenue guidance is $825 million–$855 million, a range whose midpoint is above the $832.9 million consensus estimate. Collegium also announced a $50 million accelerated share repurchase. Collegium Q3 2026 results
• Neutral Sentiment: Needham lowered its price target from $46 to $44 but maintained a Buy rating, indicating continued optimism alongside a more cautious valuation. Needham lowers Collegium price target
• Negative Sentiment: Piper Sandler cut its target sharply, from $43 to $28, and assigned a Neutral rating. The lower valuation outlook could weigh on sentiment despite the target remaining above the referenced share price. Piper Sandler rating
• Negative Sentiment: EPS declined from $2.25 in the year-ago quarter to $1.96, tempering the earnings beat. Collegium Q3 earnings

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for pain management and central nervous system disorders. The company primarily serves the U.S. market and emphasizes products designed to address significant patient and healthcare-provider needs.

Its pain portfolio includes Xtampza ER, an extended-release oxycodone formulation designed with abuse-deterrent properties, as well as Nucynta and Nucynta ER, which contain tapentadol and are used to treat acute and chronic pain.